The recent deal includes critical technology, a range of intellectual property assets, several cell lines, and a dedicated staff.
Uncommon, based in Cambridge, is shifting its focus from cultivated meat to therapeutics post-sale.
In addition, by integrating Uncommon Bio’s non-GMO mRNA reprogramming and saRNA differentiation technologies, Meatable is now providing a “true multi-platform cultivated meat technology offering.”
Meatable aims for this acquisition to expedite its time to market, streamline regulatory pathways globally, and adapt to diverse consumer preferences.
“I’m incredibly proud of what we’ve built at Uncommon Bio, a legacy of innovation and bold thinking in cultivated meat,” stated Benjamina Bollag, CEO of Uncommon.
“After deciding to focus on therapeutics, we sought the best home for our technology, and it’s exciting to see Meatable carry our work forward and apply it at scale. I look forward to continuing our collaboration and watching their success and global impact in the years ahead.”
Jeff Tripician, CEO of Meatable, remarked: “This acquisition is more than a strategic step – it sets a new standard for cultivated meat production. By combining two highly complementary platforms, Meatable is now equipped to reliably deliver high-quality cultivated meat at a global scale.”
This enables us to support the meat industry with a stable, secure, and future-proof supply of species like pork, beef, lamb, and poultry, ensuring business continuity and resilience in the face of increasingly uncertain times.”
Furthermore, the introduction of Uncommon Bio’s technology accelerates product development for chicken and lamb. Its non-GMO status and regulatory-ready dossier will facilitate quicker regulatory approvals across multiple regions.
Additionally, this acquisition enhances Meatable’s intellectual property portfolio with new patents and proprietary assets, thereby solidifying its position as a technological leader in cellular agriculture.
“The value of the IP is strengthened by the caliber of investors who have supported Uncommon’s mission from the start,” commented Aris de Rijke, chief technology officer at Meatable.
“We’re proud to carry forward technology that has earned the trust of such respected backers, including Apollo Projects and Lower Carbon Capital, further fueling our path toward success at scale.”
Meatable hosted the first-ever legally approved cultivated meat tasting in the EU last year, inviting various guests to sample its cultivated pork sausages.
